ENT-Department, Else Kröner-Fresenius-Stiftung Professorship, Section for Experimental Oncology and Nanomedicine, University Hospital Erlangen, Erlangen, Germany.
Nanomedicine. 2013 Oct;9(7):961-71. doi: 10.1016/j.nano.2013.05.001. Epub 2013 May 10.
To treat tumours efficiently and spare normal tissues, targeted drug delivery is a promising alternative to conventional, systemic administered chemotherapy. Drug-carrying magnetic nanoparticles can be concentrated in tumours by external magnetic fields, preventing the nanomaterial from being cleared by metabolic burden before reaching the tumour. Therefore in Magnetic Drug Targeting (MDT) the favoured mode of application is believed to be intra-arterial. Here, we show that a simple yet versatile magnetic carrier-system (hydrodynamic particles diameter <200nm) accumulates the chemotherapeutic drug mitoxantrone efficiently in tumours. With MDT we observed the following drug accumulations relative to the recovery from all investigated tissues: tumour region: 57.2%, liver: 14.4%, kidneys: 15.2%. Systemic intra-venous application revealed different results: tumour region: 0.7%, liver: 14.4 % and kidneys: 77.8%. The therapeutic outcome was demonstrated by complete tumour remissions and a survival probability of 26.7% (P=0.0075). These results are confirming former pilot experiments and implying a milestone towards clinical studies.
This team of investigators studied drug carrying nanoparticles for magnetic drug targeting (MDT), demonstrating the importance of intra-arterial administration resulting in improved clinical outcomes in the studied animal model compared with intra-venous.
为了高效治疗肿瘤并保护正常组织，靶向药物输送是传统全身化疗的一种很有前途的替代方法。载药磁性纳米颗粒可以通过外部磁场集中在肿瘤中，防止纳米材料在到达肿瘤之前被代谢负担清除。因此，在磁药物靶向（MDT）中，首选的应用方式被认为是经动脉内给药。在这里，我们展示了一种简单而多功能的磁性载体系统（水动力颗粒直径<200nm），可以有效地将化疗药物米托蒽醌积聚在肿瘤中。通过 MDT，我们观察到相对于从所有研究组织中回收的药物积累如下：肿瘤区域：57.2%，肝脏：14.4%，肾脏：15.2%。全身静脉内应用显示出不同的结果：肿瘤区域：0.7%，肝脏：14.4%，肾脏：77.8%。治疗结果表现为完全肿瘤消退和 26.7%的生存概率（P=0.0075）。这些结果证实了之前的初步实验结果，并暗示着向临床研究迈进了重要一步。
本研究小组研究了用于磁药物靶向（MDT）的载药纳米颗粒，结果表明与静脉内给药相比，动脉内给药的临床结果得到改善，这在研究的动物模型中非常重要。
